findmyKOL
Clinical trialNCT01998828TerminatedPhase 2Interventional

Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia

SponsorSierra Oncology LLC - a GSK companyEnrollment39Essential ThrombocythemiaPolycythemia Vera
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This open-label study is to determine the safety and efficacy of momelotinib in participants with either polycythemia vera (PV) or essential thrombocythemia (ET) who have not yet received treatment with a Janus kinase (JAK) inhibitor.

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

15 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia
  • Facility name not stated

    Frankston, Victoria, Australia

  • Facility name not stated

    Parkville, Victoria, Australia

Canada
  • Facility name not stated

    Vancouver, British Columbia, Canada

  • Facility name not stated

    Toronto, Ontario, Canada

  • Facility name not stated

    Montreal, Quebec, Canada

France
  • Facility name not stated

    La Tronche, France

  • Facility name not stated

    Nantes, France

  • Facility name not stated

    Paris, France

Germany
  • Facility name not stated

    Dresden, Germany

  • Facility name not stated

    Minden, Germany

United States
  • Facility name not stated

    Scottsdale, Arizona, United States

  • Facility name not stated

    Whittier, California, United States

  • Facility name not stated

    Tupelo, Mississippi, United States

  • Facility name not stated

    St Louis, Missouri, United States

  • Facility name not stated

    Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
19 Feb 2014
Primary completion
17 Mar 2015
Completion
7 May 2015
Last update posted
20 Apr 2020
Registered enrollment
39
Registry id
NCT01998828

Cross-registrations

EU-CTR / CTIS (EudraCT)2013-004105-11

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.